Cannabis and Chemotherapy-Induced Nausea and Vomiting

Not medical advice

This article is not medical advice. It summarizes published evidence for educational purposes. Chemotherapy regimens vary enormously in how nauseating they are, and antiemetic choices interact with your other medications, liver function, and cancer type. Talk to your oncologist or oncology pharmacist before adding or substituting cannabis or cannabinoid drugs. Stopping a prescribed antiemetic to use cannabis instead is a bad idea without medical supervision.

Plain-language summary

Chemotherapy can cause severe nausea and vomiting (CINV). THC, the main psychoactive cannabinoid in cannabis, reduces nausea through CB1 receptors in the brainstem and gut ^[1]. Two synthetic THC drugs — dronabinol (Marinol, Syndros) and nabilone (Cesamet) — are FDA-approved specifically for CINV in patients who haven't responded to standard antiemetics ^[2][3].

When these drugs were tested in the 1970s and 1980s, they outperformed the antiemetics available at the time (like prochlorperazine) ^[4][5]. But modern drugs — 5-HT3 antagonists like ondansetron, NK1 antagonists like aprepitant, and dexamethasone — are now the standard, and cannabinoids have not been shown to beat them. Major oncology guidelines (ASCO, NCCN, MASCC) list cannabinoids as an option for breakthrough or refractory CINV, not as first-line therapy ^[6][7].

Evidence for smoked or vaporized cannabis flower specifically treating CINV is much thinner than for the pills — most data is observational or extrapolated.

What probably works

Oral synthetic THC (dronabinol, nabilone) for acute CINV Strong evidence. A 2015 Cochrane review of 23 randomized trials found cannabinoids were more effective than placebo and at least as effective as conventional (pre-modern) antiemetics for chemotherapy-induced nausea and vomiting ^[4]. A 2001 BMJ systematic review reached similar conclusions ^[5]. Patients also frequently preferred cannabinoids over the older comparators.

Cannabinoids as add-on therapy for refractory CINV Weak / limited. Several smaller trials and the CAMP-1 study suggest adding an oral THC:CBD product (nabiximols) to standard antiemetics improves control of refractory delayed nausea, though effect sizes are modest and side effects (sedation, dizziness) are common ^[8].

The mechanism is biologically plausible: CB1 receptors in the dorsal vagal complex modulate the vomiting reflex, and CB1 agonists have antiemetic activity across multiple animal models ^[1].

What might work

Smoked or vaporized cannabis flower Weak / limited. Older trials of smoked cannabis for CINV exist but were small, used cannabis far less potent than today's, and rarely compared against modern antiemetics ^[9]. Most current evidence is patient surveys and observational studies showing patients use cannabis and report benefit — which is suggestive but not proof of efficacy.

CBD alone for nausea Weak / limited. Preclinical work suggests CBD has antiemetic effects via 5-HT1A receptors ^[10], but high-quality human CINV trials of CBD monotherapy are essentially absent. Marketing claims well outrun the data.

Cannabis for anticipatory nausea (the conditioned nausea that develops before chemo sessions) Weak / limited. Preclinical models suggest cannabinoids may help ^[10], but human trials are limited and standard treatment is behavioral therapy plus benzodiazepines.

What doesn't work or has weak evidence

• Cannabis as a replacement for modern triple-therapy antiemetics (5-HT3 antagonist + NK1 antagonist + dexamethasone) in highly emetogenic chemotherapy No data. No trial has shown cannabinoids match this regimen.
• Topical cannabis for nausea No data. There is no plausible pharmacokinetic basis and no trial evidence.
• Specific 'indica vs sativa' choices for nausea No data. This is dispensary folklore; the indica vs sativa distinction does not reliably predict chemical content or clinical effect.
• Specific terpene profiles (e.g. myrcene, limonene) chosen for antiemetic effect No data. Interesting preclinical signals exist for some terpenes, but no clinical CINV evidence.

What we don't know

• Whether inhaled cannabis is non-inferior to oral cannabinoids for CINV in head-to-head trials on modern chemotherapy regimens. Almost no such trials exist.
• Optimal THC:CBD ratios for nausea control vs. side-effect burden.
• How cannabis interacts with specific chemotherapy drugs metabolized through CYP3A4 and CYP2C9 — there are pharmacokinetic concerns but limited clinical data ^[11].
• Whether long-term cannabis use during chemotherapy affects treatment outcomes (tumor response, survival). Some retrospective signals exist around immunotherapy interactions but data are very preliminary ^[12].
• Pediatric oncology: nabilone has some pediatric data; smoked/vaporized cannabis essentially none.

Comparison with standard treatments

Modern CINV prophylaxis for highly emetogenic chemotherapy (like cisplatin or AC regimens) typically combines:

1. A 5-HT3 receptor antagonist (ondansetron, palonosetron)
2. An NK1 receptor antagonist (aprepitant, fosaprepitant, rolapitant)
3. Dexamethasone
4. Sometimes olanzapine

This combination achieves complete response (no vomiting, no rescue meds) in roughly 70–80% of patients in modern trials ^[6][7]. Cannabinoids have never been shown to beat this regimen. They're typically added when this regimen fails — i.e. for breakthrough or refractory CINV, where ASCO and NCCN list dronabinol/nabilone as reasonable options alongside olanzapine, lorazepam, or metoclopramide ^[6][7].

For patients with mild to moderately emetogenic regimens, or those who cannot tolerate standard antiemetics, cannabinoids may have a larger relative role.

Risks and side effects

Common cannabinoid side effects in CINV trials ^[4][5]:

• Sedation, dizziness, dry mouth (very common)
• Dysphoria, anxiety, paranoia — particularly in older patients and cannabis-naïve users
• Orthostatic hypotension
• Tachycardia

Dropout rates from side effects in older trials were notable — some patients found the psychoactive effects worse than the nausea. Nabilone and dronabinol are more predictable than inhaled cannabis because dose is fixed.

Other considerations:

• Drug interactions: THC and CBD inhibit several CYP450 enzymes; this matters for some chemotherapy agents and for warfarin, tacrolimus, and others ^[11].
• Smoking risk in immunocompromised patients: combustion produces particulates and potential fungal/bacterial contamination. Vaporization or oral routes are preferred during neutropenia.
• Cannabis hyperemesis syndrome (CHS): paradoxically, chronic heavy cannabis use can cause cyclic vomiting. This is rare but worth knowing — see Cannabis Hyperemesis Syndrome.
• Cancer outcomes: preliminary data suggest cannabis may blunt response to checkpoint-inhibitor immunotherapy ^[12]. This is not settled but is a reason to discuss cannabis use openly with oncologists, especially for patients on immunotherapy.

Sources

How this page was made

Related

• Cannabis Hyperemesis Syndrome (CHS) — A paradoxical syndrome of cyclic vomiting in chronic cannabis users that resolves only wit...